Literature DB >> 10090133

Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing's disease.

E Arvat1, J Ramunni, R Giordano, B Maccagno, F Broglio, A Benso, R Deghenghi, E Ghigo.   

Abstract

Hexarelin (HEX) is a peptidyl GH secretagogue (GHS) which markedly stimulates GH release but, like other GHS, possesses also CNS-mediated ACTH- and cortisol-releasing activity. Interestingly, the stimulatory effect of HEX on ACTH and cortisol release is exaggerated and higher than that of hCRH in patients with Cushing's disease (CD). To further clarify the mechanisms by which HEX stimulates the activity of hypothalamo-pituitary-adrenal (HPA) axis in man, in 6 patients with CD (6 women, 38-68 yr old) and in 7 control subjects (CS, 7 women, 22-29 yr old) we studied the effects of HEX (2.0 microg/kg i.v.) and/or hCRH (2.0 microg/kg i.v.) on ACTH and cortisol (F) secretion. The GH responses to HEX alone and combined with hCRH were also studied in all subjects. Basal ACTH and F levels in CD were higher than in CS (66.3+/-5.1 vs 16.5+/-0.6 pg/ml and 217.8+/-18.5 vs 134.4+/-4.6 microg/l, respectively; p<0.02). In CS, the ACTH and F responses to HEX, evaluated as deltaAUC (mean+/-SE: 128.7+/-39.2 pg x min/ml and 328.5+/-93.2 microg x min/l, respectively) were lower, though not significantly, than those after hCRH (375.8+/-128.4 pg x min/ml and 1714.2+/-598.0 microg x min/l, respectively), though the peak ACTH and F responses to both stimuli were similar. The co-administration of HEX and hCRH had an additive effect on both ACTH (1189.6+/-237.2 pg x min/ml) and F secretion (3452.9+/-648.6 microg x min/l). In fact, the ACTH and F responses to HEX+/-hCRH were significantly higher (p<0.01) than those elicited by single stimuli. In CD, HEX induced ACTH and F responses (3603.8+/-970.7 pg x min/ml and 10955.9+/-6184.6 microg x min/l, respectively) clearly higher (p<0.002) than those in CS. The HEX-induced ACTH and F responses in CD were higher, though not significantly, than those recorded after hCRH (1432.7+/-793.5 pg x min/ml and 4832.7+/-2146.5 microg x min/l, respectively). On the other hand, the hCRH-induced ACTH and F responses in CD were similar to those in CS. In CD, the coadministration of HEX and hCRH had an additive effect on ACTH (8035.7+/-1191.1 pg x min/ml) but not on F (10985.4+/-3900.8 microg x min/l) secretion. In fact, the ACTH, but not the F response to HEX+hCRH was significantly higher (p<0.02) than that elicited by single stimuli. In conclusion, the present study demonstrates that in patients with Cushing's disease as well as in subjects control Hexarelin and hCRH have an additive effect on ACTH secretion. Considering that, at least in humans, differently from hCRH, GHS have no interaction with AVP, our present findings further agree with the hypothesis that the ACTH-releasing activity of GHS is, at least partially, independent of CRH-mediated mechanisms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10090133     DOI: 10.1007/BF03345474

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.

Authors:  E Ghigo; E Arvat; J Ramunni; A Colao; L Gianotti; R Deghenghi; G Lombardi; F Camanni
Journal:  J Clin Endocrinol Metab       Date:  1997-08       Impact factor: 5.958

2.  Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites.

Authors:  E E Codd; A Y Shu; R F Walker
Journal:  Neuropharmacology       Date:  1989-10       Impact factor: 5.250

Review 3.  Peptidomimetic regulation of growth hormone secretion.

Authors:  R G Smith; L H Van der Ploeg; A D Howard; S D Feighner; K Cheng; G J Hickey; M J Wyvratt; M H Fisher; R P Nargund; A A Patchett
Journal:  Endocr Rev       Date:  1997-10       Impact factor: 19.871

Review 4.  Growth hormone-releasing peptides.

Authors:  E Ghigo; E Arvat; G Muccioli; F Camanni
Journal:  Eur J Endocrinol       Date:  1997-05       Impact factor: 6.664

5.  Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in humans.

Authors:  E Arvat; B Maccagno; J Ramunni; L Di Vito; F Broglio; R Deghenghi; F Camanni; E Ghigo
Journal:  Neuroendocrinology       Date:  1997-12       Impact factor: 4.914

6.  Widespread transcription of the growth hormone-releasing peptide receptor gene in neuroendocrine human tumors.

Authors:  Y de Keyzer; F Lenne; X Bertagna
Journal:  Eur J Endocrinol       Date:  1997-12       Impact factor: 6.664

7.  Growth hormone-releasing peptide and its analogues Novel stimuli to growth hormone release.

Authors:  M Korbonits; A B Grossman
Journal:  Trends Endocrinol Metab       Date:  1995-03       Impact factor: 12.015

8.  A receptor in pituitary and hypothalamus that functions in growth hormone release.

Authors:  A D Howard; S D Feighner; D F Cully; J P Arena; P A Liberator; C I Rosenblum; M Hamelin; D L Hreniuk; O C Palyha; J Anderson; P S Paress; C Diaz; M Chou; K K Liu; K K McKee; S S Pong; L Y Chaung; A Elbrecht; M Dashkevicz; R Heavens; M Rigby; D J Sirinathsinghji; D C Dean; D G Melillo; A A Patchett; R Nargund; P R Griffin; J A DeMartino; S K Gupta; J M Schaeffer; R G Smith; L H Van der Ploeg
Journal:  Science       Date:  1996-08-16       Impact factor: 47.728

9.  Effects of dexamethasone and alprazolam, a benzodiazepine, on the stimulatory effect of hexarelin, a synthetic GHRP, on ACTH, cortisol and GH secretion in humans.

Authors:  E Arvat; B Maccagno; J Ramunni; L Di Vito; L Gianotti; F Broglio; A Benso; R Deghenghi; F Camanni; E Ghigo
Journal:  Neuroendocrinology       Date:  1998-05       Impact factor: 4.914

10.  Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles.

Authors:  T Jacks; G Hickey; F Judith; J Taylor; H Chen; D Krupa; W Feeney; W Schoen; D Ok; M Fisher
Journal:  J Endocrinol       Date:  1994-11       Impact factor: 4.286

View more
  5 in total

1.  GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP.

Authors:  J H A Oliveira; J G H Vieira; J Abucham; A M J Lengyel
Journal:  J Endocrinol Invest       Date:  2003-03       Impact factor: 4.256

2.  Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.

Authors:  Silvia Regina Correa-Silva; Sérgio Oliva Nascif; Ana-Maria Judith Lengyel
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

3.  GH-releasing peptide (GHRP-6)-induced ACTH release in patients with addison's disease: effect of glucocorticoid withdrawal.

Authors:  M R A Martins; A C A R Pinto; E Brunner; M R D Silva; A M J Lengyel
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

4.  In vivo response to growth hormone-releasing peptide-6 in adrenocorticotropin-dependent Cushing's syndrome by lung carcinoid tumor is associated with growth hormone secretagogue receptor type 1a mRNA expression.

Authors:  M C Machado; S V Sá; T S Goldbaum; M Catania; V C Campos; M L Corrêa-Giannella; D Giannella-Neto; L R Salgado
Journal:  J Endocrinol Invest       Date:  2007-04       Impact factor: 4.256

5.  Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice.

Authors:  Rasha Mosa; Lili Huang; Yeda Wu; Chungyan Fung; Oshini Mallawakankanamalage; Derek LeRoith; Chen Chen
Journal:  Endocrinology       Date:  2017-10-01       Impact factor: 4.736

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.